



## ASX and Media Release

### **Viralytics comment on results from Amgen Phase 3 trial in melanoma patients Amgen achieve landmark in the field of oncolytic virotherapy**

---

**22 March 2013. Sydney, Australia: Viralytics Limited (ASX: VLA, OTC: VRACY)**

Biotech and Health Sciences giant Amgen (NASDAQ:AMGN), this week released top line results on its oncolytic virotherapy investigational product, Talimogene Laherparepvec (T-Vec).

Amgen reported that its phase III study in over 400 late stage melanoma patients met the primary endpoint of superior durable response rate defined as the rate of complete or partial response lasting continuously for at least six months in T-Vec versus control treated patients.

T-Vec is an investigational product based on a genetically modified cancer killing herpes virus injected directly into the tumour. Amgen acquired the technology through its purchase of BioVex in 2011 for up to \$1 billion including a \$425 million upfront payment.

Viralytics Chief Executive Officer, Dr Malcolm McColl said: "This is a milestone event for the field of oncolytic virotherapy with success in meeting the primary endpoint in a controlled phase III study. Amgen's achievement reflects well on our sector of targeted cancer biologics, encouraging further pivotal clinical evaluation of such novel oncolytic agents."

Viralytics' lead investigational product is CAVATAK™, a proprietary formulation of the genetically unmodified human Coxsackievirus A21 (involved in common cold infection). CAVATAK™ is currently under assessment at multiple sites in the US in a Phase II CALM (CAVATAK™ in Late Stage Melanoma) trial with 25 patients presently enrolled. The CALM study interim efficacy milestone of 3 or more complete or partial response responses in the first 35 patients has already been achieved. The company also plans to assess CAVATAK™ in a Phase I/II Multi-dose Intravenous STORM (Systemic Treatment Of Resistant Malignancies) clinical trial to be conducted at three prestigious cancer centres in the UK.

#### **Enquiries:**

**Dr Malcolm McColl**  
Chief Executive Officer  
02 9988 4000

**Rudi Michelson**  
Monsoon Communications  
03 9620 3333

---

**About Viralytics Ltd:** Viralytics is listed on the Australian Securities Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics' principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics' proprietary formulation of the Coxsackievirus Type A21 (CVA21). CVA21 and EV1 are viruses that occur naturally in the community. CVA21 and EV1 attach to the outside of cells, using a specific 'receptor' on the cell's surface (like a key fitting a lock). CVA21 uses the receptors, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF) to bind and infect target cells. Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including melanoma, prostate cancer, breast cancer, multiple myeloma and others. EV1 uses the receptor, integrin α2β1 (alpha 2 beta 1) receptor to bind and infect target cells. Integrin α2β1 (alpha 2 beta 1) has been demonstrated to be highly expressed on multiple cancer types, including prostate cancer, ovarian cancer and others.